Detalles de la búsqueda
1.
Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Future Oncol
; 20(12): 761-780, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38231045
2.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916267
3.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565
4.
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Breast Cancer Res
; 18(1): 67, 2016 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27349747
5.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
6.
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol
; 42(9): 994-1000, 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252901
7.
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
Target Oncol
; 18(4): 543-558, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37428347
8.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
J Clin Oncol
; 41(11): 1965-1971, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018919
9.
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptorâpositive/human epidermal growth factor receptor 2ânegative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Breast
; 66: 324-331, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36463643
10.
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Asia Pac J Clin Oncol
; 18(6): 560-569, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34908235
11.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Clin Cancer Res
; 28(16): 3433-3442, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35552673
12.
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.
Clin Pharmacol Ther
; 111(1): 302-309, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34668577
13.
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Breast
; 59: 321-326, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34388698
14.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med
; 356(2): 115-24, 2007 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-17215529
15.
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Value Health
; 12(4): 580-6, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19900256
16.
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Eur J Cancer
; 101: 123-133, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30053671
17.
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Clin Genitourin Cancer
; 5(3): 232-4, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17239278
18.
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA
; 295(21): 2516-24, 2006 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16757724
19.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 56(12): 3320-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25813205
20.
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Cancer Chemother Pharmacol
; 73(1): 151-61, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24220935